It’s hard to believe that we are wrapping up the first year of the Oregon Psilocybin Services (OPS) program. Final rules were released at this time last year, following a protracted, two-year development period. The application window for licenses opened timely on January 2, 2023, and the Oregon Health Authority (OHA) continues to administer this
A few months ago, I wrote a post entitled “Making Money in the Psychedelics Industry Will be Harder than Cannabis.” The post was focused mostly on hardships that state-legal psilocybin businesses will face in places like Oregon and Colorado, where I think the deck is heavily stacked against them. Today I want to examine a
Many ketamine clinics in the United States offer treatments for various behavioral health conditions, including depression. However, many healthcare providers who work for these clinics are not trained in psychiatry and/or counseling. There are various legal issues with this type of fact pattern. Among other things, are healthcare providers who are not trained in psychiatry
Perhaps inevitably, lawmakers introduced a very skinny bill last week to protect states that legalize psilocybin from federal intervention. Specifically, it requires that: [n]o Federal funds may be used to prevent any State or unit of local government from implementing such State’s or unit of local government’s own laws that authorize the use, distribution, sale,
There is a lot of misinformation floating around online about SB-58, California’s newest psychedelics bill. Unlike the state’s last attempt, SB-58 went through both the state Senate and Assembly and is heading to Governor Newsom’s desk. So it makes sense to discuss what the bill does and doesn’t do. And no, it doesn’t legalize psychedelics.
Ketamine telehealth has been a wild ride these last few years. Every few months I give an update, and every time I do, things seem to change dramatically. For example, in just a few short weeks in February 2023, the situation went from “bad” to “good” (at least sort of) as it became clear that
A handful of entities are in various stages of the FDA approval process for MDMA and psilocybin drugs (see here and here for some of our prior analysis of the issues). FDA approval could happen in the next few years. But there’s a catch: psilocybin and MDMA are both schedule I drugs under the Controlled Substances Act (CSA).
At the kickoff of the Oregon legislative session in January, I wrote Oregon Psilocybin 2023: Legislative Forecast and Report. The session went awry in April, when Oregon Senate Republicans staged a walkout over gun and abortion bills. The walkout lasted six weeks, with our representatives re-opening for business on June 15th— just 10 days before sin die on
Anyone familiar with the cannabis industry knows how difficult it is to make money. Things are going to be even worse for people in the state-legal psychedelics industry – much worse. There are a few key reasons for this. I should note that this post is focused on the state-legal psychedelics industry (i.e., service centers)
Section 501(c)(3)Â of the Internal Revenue Code provides tax exemptions for qualifying charitable organizations, like religious groups. Naturally, religious groups that use psychedelics want 501(c)(3) status. But the Internal Revenue Service (IRS) – like many of its counterpart agencies – refuses to play ball. In 2021, a group called the Iowaska Church of Healing took the
